Inställningar

Split view

Short keys for navigating in split view

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Dark Mode

Set dark mode to MFN.se

Sound

Plays a notification sound when new press release is published in the current feed

Intresserad av platformen MFN för nyhetsdistribution?

Onsdag 28 Oktober | 20:04:27 Europe / Stockholm

Svenska | English

Investor Relations

Public Relations

Redeye

Bifogade filer

Ultimovacs Q3 2023 - Sights set on INITIUM top-line data in H1 2024e

Prenumeration

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

Ultimovacs Q3 2023 - Sights set on INITIUM top-line data in H1 2024e

2023-11-09 08:22:00

Redeye comments on Ultimovacs’ Q3 2023 report, with recently presented NIPU survival data paving UV1’s path to phase III trials in mesothelioma. All eyes are now set on INITIUM top-line data, set for communication in March or April 2024e. We do some housekeeping in our model and adjust our valuation.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/